Peel Hunt restated their buy rating on shares of RS Group (LON:RS1 – Get Rating) in a report issued on Tuesday, Marketbeat.com reports. They currently have a GBX 1,100 ($13.41) price target on the stock.
RS1 has been the topic of a number of other research reports. Shore Capital raised shares of RS Group to a hold rating in a report on Tuesday. Morgan Stanley initiated coverage on shares of RS Group in a report on Thursday, February 16th. They set an equal weight rating and a GBX 950 ($11.58) target price on the stock. Finally, Berenberg Bank boosted their target price on shares of RS Group from GBX 1,010 ($12.31) to GBX 1,050 ($12.80) and gave the company a hold rating in a report on Tuesday, February 21st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Hold and an average target price of GBX 1,038.33 ($12.65).
RS Group Trading Up 1.9 %
Shares of RS1 stock opened at GBX 922 ($11.24) on Tuesday. The company’s fifty day simple moving average is GBX 961.99 and its two-hundred day simple moving average is GBX 967.06. The company has a debt-to-equity ratio of 29.28, a current ratio of 2.01 and a quick ratio of 1.24. RS Group has a 1 year low of GBX 790 ($9.63) and a 1 year high of GBX 1,169 ($14.25). The stock has a market capitalization of £4.36 billion, a price-to-earnings ratio of 1,646.43, a PEG ratio of 1.85 and a beta of 0.86.
RS Group Company Profile
RS Group plc, together with its subsidiaries, distributes various electronics and industrial products in the United Kingdom, the United States, France, Germany, Italy, and internationally. The company provides industrial interconnect and test, industrial automation and control, board-level electronics, and single-board computing products; and tools, consumables, and facilities maintenance products, such as personal protective equipment, site safety products, and 3D printing products.
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for RS Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RS Group and related companies with MarketBeat.com's FREE daily email newsletter.